Trial Profile

A Multinational, Randomized, Open-Label, Phase 3 Study Of Sunitinib Malate [sunitinib] Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Apr 2022 Results assessing a clinical prediction tool for predicting severe hand-foot syndrome published in the Cancer Chemotherapy and Pharmacology
26 Mar 2022 This trial has been completed in Belgium (End Date: 08 Dec 2011), according to European Clinical Trials Database record.
28 Sep 2020 Results evaluating the impact of PPI use on the survival outcomes of advanced HCC patients treated with sorafenib published in the Journal of Cancer Research and Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com